Delving into the Latest Updates on APH01727 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target

GLP-1R

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2ObesityDiabetes Mellitus

Inactive Indication-

Originator Organization

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Active Organization

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

ApicHope Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

(1) Primary purpose: To evaluate the safety, tolerability and pharmacokinetic characteristics of APH01727 tablets after single and multiple oral administration in healthy adults (2) Secondary purpose: To evaluate the effect of food on the pharmacokinetics of APH01727 tablets after single oral administration in healthy adults To evaluate the pharmacodynamic effects of APH01727 tablets after multiple oral administration in healthy adults

Start Date-

Sponsor / Collaborator

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

100 Clinical Results associated with APH01727

Login to view more data

100 Translational Medicine associated with APH01727

Login to view more data

100 Patents (Medical) associated with APH01727

Login to view more data

100 Deals associated with APH01727

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 1	CN	Guangzhou Yipinhong Pharmaceutical Co., Ltd.	26 Jul 2024
Obesity	IND Approval	CN	Guangzhou Yipinhong Pharmaceutical Co., Ltd.	23 Jul 2024
Diabetes Mellitus	IND Application	CN	ApicHope Pharmaceutical Co., Ltd.	14 May 2024